900
Views
30
CrossRef citations to date
0
Altmetric
Original Article

Adult ADHD: prevalence of diagnosis in a US population with employer health insurance

, , , &
Pages 5-11 | Accepted 04 Jul 2011, Published online: 05 Oct 2011
 

Abstract

Objective:

The burden of attention-deficit/hyperactivity disorder (ADHD) in adults is increasingly recognized. This retrospective analysis was designed to estimate the prevalence of diagnosed ADHD in a population of insured, employed individuals and their dependents in the United States.

Methods:

Health care claims data obtained from the MarketScan Commercial Claims and Encounters Database were analyzed. Patients with ADHD were identified by at least two diagnostic claims per calendar year. Once identified, patient records were examined for evidence of continuing ADHD.

Results:

Between 2002 and 2007, the MarketScan database identified 342,284 patients with more than one claim for ADHD. Of these, 79,368 patients met the eligibility for the prevalence estimates. During the study period, the prevalence of diagnosed ADHD among adults increased more than three-fold: 1.24 to 4.02 cases per 1000 covered members. The largest proportion of cases was in the 18–24 years age group (42.8%–45.8% per year). Most cases were males; however, the ratio of females-to-males diagnosed increased over time. ADHD with hyperactivity was prevalent across all age groups analyzed, although more common in the 18–24 years group. Pharmacy claims showed patients receiving medical treatment for ADHD increased from 78% to 88.5%. A limitation of this study is that it is restricted to employed persons and their dependents. Thus, the results from this database may underestimate the true prevalence of diagnosed ADHD in the US population.

Conclusions:

While the claims database used included employed insured persons and dependents only, study results highlight the rising prevalence of diagnosed ADHD in a US adult population. The prevalence increased more than three-fold from 2002 to 2007 with the largest increase in the 18–24 years age group. These findings on ADHD prevalence highlight the need for greater attention to the medical treatment of this disorder in different age groups, particularly in young adults.

Transparency

Declaration of funding

Thomson Reuters was funded by Shire Development Inc. to conduct this study. MarketScan is a registered trademark of Thomson Reuters (Healthcare) Inc. R.S., P.H., and L.R. contributed towards the study design and manuscript writing.

Declaration of financial/other relationships

P.H. and L.R. are full-time employees of Shire Development Inc. and own stock in the company. R.S. was a full-time employee of Shire Development Inc. at the time of this study. D.H. and L.M. are both full-time employees of Thomson Reuters, who were employed to carry out the analysis. MarketScan is a registered trademark of Thomson Reuters (Healthcare) Inc.

Acknowledgements

The authors would like to acknowledge the writing assistance of Phil Matthews, PhD (PAREXEL) in the preparation of this manuscript. Financial support for this assistance was provided by Shire Development Inc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.